ClinicaliQ Trial Snapshot
- A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia — Recruiting • Phase III • Oncology • NCT04307576.
- What is being tested: ALLTogether is a master protocol that consolidates evidence-based treatment approaches for acute lymphoblastic leukaemia (ALL) across infants, children, and young adults (0-45 years), incorporating expertise from multiple established study groups to optimise stratification and treatment strategies.
- Patient eligibility overview: The trial includes participants aged 0-45 years with newly diagnosed or relapsed ALL, with stratification based on prognostic factors to tailor treatment intensity and approach to individual patient risk profiles.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
ALLTogether collects the experience of previously successful treatment of infants, children and young adults, with ALL from a number of well-renowned study groups into a new master protocol, which is both a comprehensive system for stratification and treatment of ALL in this age-group as well as the basis for several randomised and interventional trials included in the study-design.
Eligibility Snapshot
- : * Patients newly diagnosed with T-lymphoblastic (T-cell) or B-lymphoblastic precursor (BCP) leukaemia (ALL) according to the WHO-classification of Tumours of Haematopoetic and Lymphoid Tissues (Revised 4th edition 2017) and with a diagnosis confirmed by an accredited laboratory at a participating paediatric oncology or adult haematology centre. * Age 0 - < 46 years (one day before 46th birthday) at the time of diagnosis with the exception of infants with KMT2A-rearranged (KMT2A-r) BCP ALL. * Patients with surface immunoglobulin negative (sIG-) BCP-ALL and an IG::MYC rearrangement, unless they have a concurrent BCL2/6 rearrangement. T-ALL patients with MYC translocations. * Informed consent signed by the patient and/or parents/legal guardians according to country-specific age-related guidelines. * The ALL diagnosis should be confirmed by an accredited laboratory at a participating paediatric oncology or adult haematology centre. * The patient should be diagnosed and treated at a participating paediatric oncology or adult haematology centre in the participating countries. * The patient should be a resident in one of the participating countries on a permanent basis or should intend to settle in a participating country, for instance by an application for asylum. Patients who are visiting the country as tourists should not be included.…
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.